The atypical chemokine receptor D6 is a decoy and scavenger receptor for most inflammatory CC chemokines and prevents the development of exacerbated inflammatory reactions. Here we report that mice lacking D6 expression in the non-hematopoietic compartment have a selective increase in the number of Ly6C high monocytes in the circulation and in secondary lymphoid tissues. Under inflammatory conditions, Ly6C high monocytes accumulate in increased number in secondary lymphoid organs of D6 -/-mice in a CCR2-dependent manner. Ly6C high monocytes derived from D6
For personal use only. on . by guest www.bloodjournal.org From
INTRODUCTION
The chemokine system represents the main orchestrator of leukocyte recruitment [1] [2] [3] [4] . Among several regulatory mechanisms, a prominent role has been recently recognized to a set of chemokine receptors indicated as atypical in that structurally unable to directly mediate cell migration 5 .
Atypical chemokine receptors are structurally and functionally heterogeneous, but they share the biological role of regulating signaling receptors' activity, by clearance, transport or presentation of their cognate ligands [5] [6] [7] . D6 is one of these atypical chemokine receptors, and its main function is to bind and drive to degradation the majority of inflammatory CC chemokines [8] [9] [10] . By this chemokine scavenger function, D6 acts as a negative regulator of inflammation, as demonstrated by D6-deficient mice that are characterized by increased levels of inflammatory CC chemokines and development of exaggerated inflammatory reactions in different organs expressing D6 on lymphatic vessels 11 , including skin 12, 13 , liver 14 , colon 15, 16 , lungs 17, 18 , and placenta, where its expression is restricted to trophoblast cells 19 . On the contrary, in certain conditions the uncontrolled local inflammation observed in D6 -/-mice has been shown to impair the development of specific immune responses, protecting mice from development of autoimmune diseases 20 . Although D6 -/-mice have been investigated extensively, several aspects of D6 biology, including the precise mechanisms by which it regulates inflammatory responses, are not yet fully understood.
In recent years it became evident that inflammatory CC chemokines control not only monocyte recruitment at inflammatory sites but also regulate monocyte homeostasis and mobilization from the BM in infectious and hypercholesterolemia models [21] [22] [23] . Based on the expression of the myeloid differentiation antigen Ly6C and the chemokine receptors CCR2 and CX3CR1, two phenotypic and functional monocyte subsets have been described in mice 24 .
Classical monocytes are Ly6C 27 . This population consists of cells of myeloid origin (CD11b + ) that are labeled by the specific antibody to Gr1 that recognizes both the Ly6C and the Ly6G markers on monocytes and neutrophils, respectively 28 . Here we report that D6 expressed on non-hematopoietic compartment controls the traffic of monocyte subsets in a CCR2-dependent manner. In its absence, the immunosuppressive properties of Ly6C high monocytes are unleashed, resulting in a partial protection from the development of Graft-versus-Host Disease (GvHD).
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MATERIALS AND METHODS
Reagents
Human CCL2 and Fluorokine® MAP Mouse Multianalyte Profiling Base Kit or ELISA Kits were from R&D Systems (Minneapolis, MN). When not specified reagents were purchased from SigmaAldrich (St. Louis, MO). Anti-DEC205 OVA-conjugated was provided by F. Benvenuti. Depleting anti-Gr1 (RB6-8C5) antibody and rat IgG2b isotype control (inoculated i.p. 200 μg, every 3 days) were purchased from BioXCell (West Lebanon, NH).
Animals
The generation and genotyping of B6 D6 -/-mice have been described previously 13 ; mice were backcrossed onto the BALB/c background for 10 generations. B6 OVA-specific, TCR transgenic (OT-I) mice were purchased from Jackson Laboratories (Bar Harbor, ME) and crossed with B6 CD45.1 mice (Ly5.1). B6 Ly5.1 WT and CCR2 -/-mice were purchase from Jackson Laboratories.
All colonies were maintained in a specific pathogen-free/viral antibody-free barrier facility at 
Quantitative RT-PCR
Total RNA was extracted from MDSC with miRNA easy Mini kit (Qiagen, Germany). Reverse transcription was done using High Capacity cDNA Reverse Trascription Kit (Applied Biosystems;
Warrington, UK). Quantitative PCR was performed with TaqMan® Gene Expression Assays in a 7900 HT Fast-Real Time PCR System (Applied Biosystems). ). The reverse experiments were performed using irradiated B6 WT or D6 -/-mice (900 cGy) as recipients and BALB/c BM (1x10 7 cells) and splenocytes (3x10 7 ). Mice were monitored every two days after transplant for survival and by a standard scoring system described previously 30 .
Mixed leukocytes reaction (MLR) and in vitro T cell proliferation
Statistical analysis
Data were analyzed by unpaired Student's t test. Survival curves were compared using log-rank test with GraphPad Prism4 software.
RESULTS
Increased Ly6C
high monocytes in blood and spleen of D6 -/-mice.
D6
-/-mice display enhanced serum chemokine titers both in homeostatic and inflammatory conditions and show an increased inflammatory response in several in vivo models [12] [13] [14] [15] [16] [17] [18] [19] . In order to understand how inflammatory chemokine scavenging performed by D6 impacts on homeostatic leukocyte traffic, analysis of leukocytes in blood, spleen, and BM cells was performed. No To understand if these modifications are related to D6 expression on haematopoietic cells or lymphatic vessels, BM transfer experiments were performed. After 15 weeks of BM engraftment the increased number of circulating monocytes was only observed when recipient mice were D6 -/-, independently from the genotype of donor cells (Fig. 1e) , indicating that the phenotype was not due to an intrinsic defect of D6 -/-leukocytes but to the absence of D6 expression on the nonhematopoietic compartment, possibly the lymphatic vessels which express D6 at high levels 11 .
Mobilization of BM leukocytes under inflammatory conditions
Myeloid populations in different compartments of D6 -/-and WT mice were compared after subcutaneous injection of CFA, an inflammatory challenge previously shown to induce anticipated 2g and data not shown). Of note, in splenectomized animals D6 -/-mice showed an increased amount of circulating monocytes also after CFA injection (Fig. 2g) .
Accumulation of Ly6C high monocytes in lymphoid organs is a CCR2-dependent mechanism 21, 22, 33 .
In order to understand if CCL2/CCR2 axis was involved in the increased accumulation of Ly6C high monocytes found in D6 -/-mice, two parallel approaches were performed. First, CCL2 was intravenously injected in WT and D6 -/-mice. After 4 hours the amount of CCL2 was higher in the serum of D6 -/-mice as compared to WT mice (Fig. 3a) , indicating that the chemokine clearance is significantly delayed when D6 is missing. Under these experimental conditions the total number of BM Ly6C high monocytes declined with no statistical differences between WT and D6 -/-mice (data not shown), but a significant increase in the absolute number of circulating inflammatory monocytes (data not shown) and, consistent with observations after CFA injection, increased number of splenic monocytes in D6 -/-as compared to WT mice, was detected (Fig. 3b) 
-/-splenocytes to proliferate (Fig. 4a) . (Fig. 4c) and proliferation ( Fig. 4d and e) within draining LNs compared to OT-I cells primed in WT mice. When mice were treated with a depleting anti-Gr1
antibody during the immunization protocol, OT-I cell proliferation was increased in both WT and D6 -/-recipients and OT-I accumulation and proliferation in D6 -/-recipients was fully restored, being comparable to that observed in WT recipients ( Fig. 4d and e) . and IFNγ production, and most importantly cells taken from D6 -/-mice were consistently more potent than cells obtained by WT mice (Fig. 5a and 5b) Figure 1c )
Increased immunosuppressive activity of D6 -/-Ly6C high monocytes
Gr1
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D6
-/-mice showed a significant reduction in the expression levels of several differentiation markers, including CD115, CD11b, and F4/80 (Fig 5ec) . CD11b was also downregulated in circulating monocytes in D6 -/-mice, both in basal conditions and after CFA challenge, while the opposite was observed for monocytes derived from CCR2 -/-mice (Fig. 5fd) . Collectively these data indicate that under homeostatic conditions lack of D6 results in the release of Ly6C high monocytes characterized by an immature phenotype, similar to those mobilized as a consequence of CCR2 activation under inflammatory conditions, and that this phenomenon is further increased when D6 -/-are challenged with inflammatory stimuli.
In order to understand the mechanism by which lack of control of inflammatory chemokines in the absence of D6 could increase Ly6C high monocyte suppressive activity, sorted
+ /Ly6C high monocytes were analyzed for expression of genes responsible for immunosuppressive activity. While no significant difference between the two groups was found for inducible nitric oxide synthases (data not shown), Ly6C high monocytes from D6 -/-mice displayed increased expression of arginase 1 (ARG1) and COX2 (Fig. 5e ). The role of COX2 and ARG1 in the suppressive activity of D6 -/-monocytes was further demonstrated by the use of specific inhibitors (SC-58125 and BEC respectively) that were able to significantly recover proliferation of T cells cultured with D6 -/-but not WT monocytes (Fig 5f) . CCL2 was previously reported to sustain an autocrine pathway leading to COX2 upregulation in human monocytes 35 . Similarly, in BMderived macrophages (BMDM) from WT but not CCR2 -/-mice CCL2 upregulated COX2 and ARG1 expression levels (Fig. 5hg) . These data indicate that delayed inflammatory chemokine clearance in the absence of D6 not only induces accumulation of immature Ly6C high monocytes in blood and secondary lymphoid organs, but also increases their suppressive capacity by inducing COX2 and ARG1 expression.
Delayed GvHD development in D6 -/-mice
The ability of D6 -/-Ly6C high monocytes to suppress specific immune responses was further assessed
in vivo in a GvHD model induced by the transfer of WS and BM cells from allogeneic (WT
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BALB/c) donors in lethally irradiated WT or D6
-/-B6 recipients. The two cohorts exhibited similar disease activity at early time points, when acute GvHD is typically at its peak. At later time points, WT B6 mice developed a severe GvHD and died by day 60, while D6 -/-recipient mice showed a significant reduction in GvHD manifestations and an increased survival rate (Fig. 6a and b) .
Consistent with this, both the number of infiltrating CD4 + and CD8 + effector cells ( Fig. 6c and d) as well as IFNγ and CCL2 levels ( Fig. 6e and f) were significantly lower in GvHD target organs (liver and gastrointestinal tract) of D6 -/-mice as compared to WT mice. Similarly, IFNγ serum concentrations were reduced (Fig. 6e) . On the contrary, circulating levels of CCL2 were higher in D6 -/-as compared to WT mice, being significantly different at the steady state and at day 16 after transplant ( Fig. 6f) .
When an acute GvHD model was performed, using BALB/c mice as recipients of allogeneic WS and BM cells from B6 donors, animals developed a more severe and rapid GvHD as compared to WT B6 recipients 36 . Consistent with results obtained in the D6 -/-B6 background, the absence of D6 in recipient mice resulted in prolonged survival and a significant delay in the disease ( Fig. 7a and b), and correlated with decreased concentrations of IFNγ (Fig. 7c ) and increased concentrations of CCL2 (Fig. 7d) in the serum. Analysis of leukocytes in LNs, spleen, and blood at day 3 after transplantation indicated that Ly6C high monocytes were increased in D6 -/-recipients as compared to control and WT BALB/c recipients (Fig. 7e) . The protective role of these leukocytes in GvHD was demonstrated by depletion experiments performed by the use of the anti-Gr1 antibody, which did not affect the mortality rate of WT mice but completely abrogated the disease delay observed in D6 -/-BALB/c mice (Fig. 7f) . Fig. 2a ). Importantly, protection was lost upon depletion of Gr1 + cells from WS taken from D6 -/-mice ( Supplementary Fig. 2b) (Fig. 7g ).
Delayed GvHD is mediated by Gr1
16
DISCUSSION
The atypical chemokine receptor D6 exerts a non-redundant role in the control of inflammation, as
D6
-/-mice are more susceptible to infections and inflammation in several models of pathology when compared to WT littermates [12] [13] [14] [15] [16] [17] [18] [19] . This phenotype has been ascribed to the exacerbation of the local inflammatory response caused by the delayed clearance and consequent increase in concentration of inflammatory CC chemokines observed in the absence of D6, which operates as a decoy and scavenger receptor for its ligands 37 . Differently from the well established role of D6 in the negative regulation of inflammatory responses, its relevance for the onset and development of adaptive immune responses is less defined, and evidence suggest that in this context it may even play an opposite role, acting as a promoter of the immune response 20 . Here we report that the control of CC chemokines by D6 has a selective impact on the traffic and differentiation/activation properties of Ly6C high monocytes, resulting in a significant inhibition of the development of adaptive immune responses.
Plasticity and diversity are hallmarks of the mononuclear phagocyte lineage, and macrophage heterogeneity and its impact on the development of innate and adaptive immune responses has long been recognized 38, 39 . Along the same line, heterogeneity in circulating monocytes is also increasingly appreciated 26 . In mice at least two different monocyte populations can be distinguished, based on the expression of the marker Ly6C
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. Among these, Ly6C high monocytes, also called classical or inflammatory monocytes for their ability to produce primary inflammatory cytokines, also represent a component of the so-called MDSC, which in different pathological conditions accumulate in blood and lymphoid organs and exert a suppressive effect on adaptive immune responses 27, 40 . Several reports have clearly demonstrated that the CCR2 agonists CCL2 and CCL7 control systemic levels of monocyte subsets by inducing their mobilization from BM 21, 22, 41 . In the tumor context CCL2 and its receptor CCR2 were found to be relevant for monocyte recruitment and survival and to promote their differentiation toward tumor-associated show that D6-deficient animals have increased concentrations of CCL2 in serum (Fig. 6f) , and we have previously reported similar data for CCL11 19 D6 is expressed by different leukocyte subsets, mainly marginal zone B cells, DC and cardiac graft-infiltrating macrophages [45] [46] [47] , but its function on these cell types has not been defined 6 . In this context, it is worth mentioning that we did not detect D6 expression on Ly6C high monocytes (data not shown), consistent with the hypothesis that the effect of D6 on their mobilization from BM is mediated by its control on the chemokine milieu. Data presented here are in agreement with previous observations 15 indicating that chemokine clearance is mainly exerted by D6 expressed on stromal cells, presumably lymphatic vessels in barrier tissues, including skin, gut, lung, and placenta 7 .
As compared to cells from WT animals, Ly6C high monocytes derived from D6 -/-mice presented a more immature phenotype, as indicated by lower expression of maturation markers including CD11b, CD115, and F4/80, a phenotype resembling the one observed under inflammatory
-/-mice. In addition, Ly6C high monocytes derived from D6 -/-mice presented a significant increase in their immunosuppressive potential both in vitro and in vivo. This is correlated with increased expression of the immunosuppressive genes COX2 and ARG1. It was previously reported that CCL2 increase COX2 expression in human monocytes, and here we report that also in murine BMDM CCL2 induces COX2 and ARG1 expression that give rise to the increased immunosuppression that indeed was blocked by specific inhibitors.
In an immunization model based on transfer of OVA-specific CD8 + cells and challenge with the cognate antigen, D6 -/-recipient mice showed a significant defect in proliferation and LN accumulation of antigen-specific T lymphocytes, and when tested in fully MHC-mismatched allogeneic GvHD models, both B6 and BALB/c D6 -/-recipients were partially but significantly protected from GvHD. In both experimental conditions the immune response was restored after depletion of Gr1 + cells, and despite the fact that the use of anti-Gr1 has some limitations 48 , it is well assessed that this antibody ablates the suppressor activity of Gr1 + myeloid cells. Thus, in the absence of D6 the BM releases increased amounts of immature Ly6C high monocytes that infiltrate lymphoid organs and exert an immunosuppressive activity.
GvHD is the most significant clinical problem that arises after allogeneic BM cell transplantation. It has been shown that T cell migration into GvHD target tissues is mediated by local chemokine production induced by the conditioning treatment. Interestingly, there is a rapid and transient chemokine increase in GvHD target tissues before T cell infiltration, and chemokine production is then amplified by the allogeneic reaction 49 . Inhibition of inflammatory chemokines 30, 50 has been associated to protection from GvHD mortality due to decreased effector cell recruitment to target tissues, and chemokines have been proposed as molecular targets for the treatment of acute GvHD.
On the contrary, here we show that in the absence of the control of inflammatory chemokines by D6
increased circulating levels of CCL2 are detectable few days after the myeloablation and transplantation procedure and that this results in increased recruitment of monocytes to lymphoid organs that give rise to partial protection from the GvHD. Indeed, though immature or M2 polarized For personal use only. on . by guest www.bloodjournal.org From 
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FIGURE 1
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